Is COWZ ETF a Good Investment?
There’s a reason even Warren Buffett advocates his heirs to…
Sell
40
SGRY Quote, Financials, Valuation and Earnings
Last price:
$19.86
Seasonality move
:
5.45%
Day range:
$20.30 - $21.20
52-week range:
$19.50 - $35.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.89x
P/B ratio:
1.42x
Volume:
1.3M
Avg. volume:
1.1M
1-year change:
-34.81%
Market cap:
$2.7B
Revenue:
$2.7B
EPS (TTM):
-$0.48
Analysts' Opinion
-
Consensus RatingSurgery Partners has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $34.02, Surgery Partners has an estimated upside of 60.76% from its current price of $21.16.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $28.00 representing -32.33% downside risk from its current price of $21.16.
Fair Value
-
According to the consensus of 12 analysts, Surgery Partners has 60.76% upside to fair value with a price target of $34.02 per share.
SGRY vs. S&P 500
-
Over the past 5 trading days, Surgery Partners has overperformed the S&P 500 by 1.79% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Surgery Partners does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Surgery Partners has grown year-over-year revenues for 17 quarters straight. In the most recent quarter Surgery Partners reported revenues of $770.4M.
Earnings Growth
-
Surgery Partners has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Surgery Partners reported earnings per share of -$0.25.
Enterprise value:
7.3B
EV / Invested capital:
--
Price / LTM sales:
0.89x
EV / EBIT:
22.63x
EV / Revenue:
2.45x
PEG ratio (5yr expected):
-0.88x
EV / Free cash flow:
44.74x
Price / Operating cash flow:
16.32x
Enterprise value / EBITDA:
15.46x
Gross Profit (TTM):
$705.6M
Return On Assets:
-0.85%
Net Income Margin (TTM):
-2.03%
Return On Equity:
-1.76%
Return On Invested Capital:
-0.95%
Operating Margin:
13.02%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $2.4B | $2.7B | $3B | $674.1M | $770.4M | |
| Gross Profit | $537.7M | $638.2M | $705.6M | $165.8M | $177.5M | |
| Operating Income | $356.2M | $388.1M | $434.3M | $101.3M | $100.3M | |
| EBITDA | $473.7M | $437.4M | $472.9M | $111.5M | $111.1M | |
| Diluted EPS | -$0.35 | -$0.32 | -$0.48 | -$0.04 | -$0.25 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $893.4M | $841.7M | $738.3M | $876.2M | $1B | |
| Total Assets | $5.3B | $5.6B | $6.5B | $6.8B | $7.5B | |
| Current Liabilities | $590.9M | $540.5M | $624.3M | $501.4M | $575.2M | |
| Total Liabilities | $3.8B | $3.8B | $4.1B | $3.5B | $4B | |
| Total Equity | $1.5B | $1.9B | $2.4B | $3.3B | $3.5B | |
| Total Debt | $2.8B | $2.9B | $3.2B | $2.7B | $3.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $171.3M | $238.4M | $251.3M | $104.6M | $65.2M | |
| Cash From Investing | -$425.7M | -$239.7M | -$434.9M | -$25.6M | -$49.6M | |
| Cash From Financing | $78.8M | $82.5M | $169.4M | -$20.4M | -$7.3M | |
| Free Cash Flow | $99.3M | $146.7M | $163.4M | $85.7M | $45M | |
SGRY
Sector
Market Cap
$2.7B
$46.7M
Price % of 52-Week High
59.95%
46.54%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-34.81%
-33.88%
Beta (5-Year)
2.585
0.752
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$20.97
200-day SMA
Sell
Level
$26.94
Bollinger Bands (100)
Sell
Level
22.66 - 31.94
Chaikin Money Flow
Sell
Level
-9.3M
20-day SMA
Buy
Level
$20.83
Relative Strength Index (RSI14)
Sell
Level
46.18
ADX Line
Buy
Level
23.78
Williams %R
Neutral
Level
-36.3985
50-day SMA
Sell
Level
$23.43
MACD (12, 26)
Sell
Level
-0.63
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Sell
Level
-24.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.1967)
Sell
CA Score
(Annual)
Level (-1.0347)
Buy
Beneish M-Score
(Annual)
Level (-2.5506)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (1.6641)
Buy
Piotroski F Score
(Annual)
Level (7)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It operates in two segments: Surgical Facility Services and Ancillary Services out of which the Surgical Facility Services segment accounts for the majority of revenue.
Stock Forecast FAQ
In the current month, SGRY has received 9 Buy ratings 3 Hold ratings, and 0 Sell ratings. The SGRY average analyst price target in the past 3 months is $34.02.
-
Where Will Surgery Partners Stock Be In 1 Year?
According to analysts, the consensus estimate is that Surgery Partners share price will rise to $34.02 per share over the next 12 months.
-
What Do Analysts Say About Surgery Partners?
Analysts are divided on their view about Surgery Partners share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Surgery Partners is a Sell and believe this share price will drop from its current level to $28.00.
-
What Is Surgery Partners's Price Target?
The price target for Surgery Partners over the next 1-year time period is forecast to be $34.02 according to 12 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is SGRY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Surgery Partners is a Buy. 9 of 12 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SGRY?
You can purchase shares of Surgery Partners via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Surgery Partners shares.
-
What Is The Surgery Partners Share Price Today?
Surgery Partners was last trading at $19.86 per share. This represents the most recent stock quote for Surgery Partners. Yesterday, Surgery Partners closed at $21.16 per share.
-
How To Buy Surgery Partners Stock Online?
In order to purchase Surgery Partners stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
3 Stocks Buffett Is Betting On
Warren Buffett appeared to take a hard look at the…
Why Did Buffett Sell So Much Last Year?
In 2024, value investing legend Warren Buffett did the seemingly…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 39x
Sell
46
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 112x
Sell
40
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
61
ITCI alert for Jan 14
Intra-Cellular Therapies [ITCI] is down 0.26% over the past day.
Sell
30
ESTA alert for Jan 14
Establishment Labs Holdings [ESTA] is down 1.51% over the past day.
Buy
72
DJT alert for Jan 14
Trump Media & Technology Group [DJT] is down 8.25% over the past day.
